Skip to main content

Table 2 PK parameters for each patient

From: Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Patient

Cmax(μg/mL)

Cmin(μg/mL)

VD (L/kg)

Ke (h–1)

CL (L/h)

t1/2(h)

AUC [0-inf]

Dose in mg/kg

1

283.97

13.29

0.26

0.53

7.45

1.31

398.78

54.05

2

200.56

16.87

0.35

0.44

8.70

1.59

419.14

52.63

4

337.21

6.36

0.22

0.69

8.15

1.01

232.15

70.18

5

211.53

18.76

0.35

0.43

8.19

1.60

446.61

46.51

6

153.13

18.74

0.61

0.36

9.30

1.95

311.08

85.11

7

97.37

3.88

0.52

0.57

23.54

1.21

163.28

63.49

8

94.10

2.22

0.65

0.64

27.25

1.08

115.12

58.82

10

465.78

13.64

0.15

0.57

4.93

1.21

607.15

86.96

11

162.34

5.18

0.42

0.53

13.13

1.30

317.32

66.67

12

179.52

37.65

0.45

0.26

5.84

2.65

418.48

60.61

13

318.81

28.34

0.26

0.44

5.48

1.59

667.45

62.50

14

319.55

19.07

0.30

0.50

6.20

1.40

477.15

78.43

15

513.74

4.52

0.10

0.82

6.38

0.85

678.99

86.96

16

1133

0.47

0.08

1.25

4.42

0.55

827.16

66.67

Mean

319.33

13.50

0.34

0.57

9.93

1.38

434.28

67.11

σ(n-1)

266.08

10.71

0.18

0.24

6.95

0.51

205.17

13.01

  1. Mentioned on page 6.